How Will the Market React to Tricida Inc (TCDA) Stock Getting a Bearish Rating

Monday, November 28, 2022 02:19 PM | InvestorsObserver Analysts

Mentioned in this article

How Will the Market React to Tricida Inc (TCDA) Stock Getting a Bearish Rating

Tricida Inc (TCDA) stock has risen 12.00% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Tricida Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on TCDA!

See Full TCDA Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With TCDA Stock Today?

Tricida Inc (TCDA) stock is higher by 34.49% while the S&P 500 has fallen -1.46% as of 2:19 PM on Monday, Nov 28. TCDA is up $0.07 from the previous closing price of $0.21 on volume of 33,715,192 shares. Over the past year the S&P 500 is down -14.78% while TCDA has fallen -96.20%. TCDA lost -$2.37 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Tricida Inc click here.

More About Tricida Inc

Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis. Click Here to get the full Stock Report for Tricida Inc stock.